Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Go back to Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults| (NASDAQ: PCVX) | Delayed: 51.44 +0.77 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.67 | 52 Week High | $ | |||
| Open | $52.00 | 52 Week Low | $ | |||
| Day High | $53.48 | P/E | N/A | |||
| Day Low | $50.24 | EPS | $ | |||
| Volume | 2,837,044 | |||||
